Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.60 |
| ▸ | PPARA | Q07869 | 16/20 | 0.60 |
| ▸ | PPARD | Q03181 | 9/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337925 | 0.89 | PPARG (0.50) | PPARGPPARAPPARDNR4A2LMNA | |
| SCHEMBL4337033 | 0.86 | PPARA (0.58) | PPARGPPARAPPARD | |
| SCHEMBL4334094 | 0.85 | PPARA (0.59) | PPARGPPARAPPARD | |
| SCHEMBL4334186 | 0.82 | PPARA (0.48) | PPARGPPARAPPARDSMN1; SMN2 | |
| SCHEMBL4339632 | 0.81 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL4335005 | 0.81 | PPARG (0.56) | PPARGPPARAPPARD | |
| SCHEMBL4339633 | 0.80 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL4332162 | 0.80 | PPARA (0.50) | PPARGPPARAPPARD | |
| SCHEMBL4346891 | 0.79 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL4348598 | 0.79 | PPARG (0.49) | PPARGPPARAPPARDNR4A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | PPARG 379/4885PPARA 339/4885PPARD 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.